KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.

Jessica R Allegretti, Paul Feuerstadt, Whitfield L Knapple, Robert Orenstein, Philippe Pinton, Alexander Sheh, Sahil Khanna

Inflamm Bowel Dis 31(8) 2112-2122

PMID39862395
PMCIDPMC12342783
DOI10.1093/ibd/izae291
发表日期2025-01-25
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Fecal microbiota, live-jslm (RBL; REBYOTA®), is the first single-dose, broad consortia, microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care antimicrobials. Inflammatory bowel disease (IBD) is a common risk factor for rCDI, yet patients with IBD are often excluded from prospective trials. This subgroup analysis of PUNCH CD3-OLS (NCT03931941) evaluated the safety and efficacy of RBL in participants with rCDI and IBD. METHODS: Participants with IBD (ulcerative colitis [UC], Crohn's disease [CD], or unspecified) who had rCDI were included. Treatment-emergent adverse event (TEAE) data were collected for up to 6 months following RBL administration. Efficacy outcomes included treatment success at 8 weeks and sustained clinical response at 6 months. RESULTS: Overall, 793 participants were enrolled, and 697 received RBL; 74 had IBD (UC: n = 45; CD: n = 25; unspecified IBD: n = 4). TEAEs within 8 weeks of administration were reported by 45.9% and 47.5% of participants with and without IBD, respectively; most were mild or moderate gastrointestinal symptoms. Serious TEAEs within 8 weeks of administration were reported by 1.4% and 4.2% of participants with and without IBD, respectively. The treatment success rate at 8 weeks was 78.9%, and the sustained clinical response rate at 6 months was 91.1% in participants with IBD, similar to rates in participants without IBD (73.2% and 91.0%, respectively). CONCLUSIONS: The results of this subgroup analysis of PUNCH CD3-OLS suggest RBL is safe and efficacious in patients with IBD.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. CONSORT diagram showing enrollment and subgroups. a Participants who had signed informed consent forms but did not meet all eligibility criteria were considered screen failures. b Participants could have >1 reason for exclusion from the modified intent-to-treat population. Abbreviations: CD, Crohn’s disease; CDI, Clostridioides difficile infection; IBD, inflammatory bowel disease; RBL, fecal microbiota, live-jslm; UC, ulcerative colitis.
非 KM Figure
Figure 2Figure 2. Efficacy outcomes within 8 wk and between 8 wk and 6 mo of RBL administration (mITT population). Treatment success within 8 wk of RBL administration in (A) participants with and without IBD and (B) participants with CD and UC (IBD subgroups). Sustained clinical response at 6 mo in 8-wk responders in (C) participants with and without IBD and (D) participants with CD and UC (IBD subgroups). a Treatment success is defined as the absence of CDI-related diarrhea through 8 wk after RBL administration. b Efficacy outcome was indeterminate if CDI test was inconclusive or missed at time of visit. Abbreviations: CD, Crohn’s disease; CDI, Clostridioides difficile infection; IBD, inflammatory bowel disease; RBL, fecal microbiota, live-jslm; mITT, modified intent-to-treat; UC, ulcerative colitis.
非 KM Figure